House dust mite allergen extract (Actair®). HTA ID: 23008

Assessment Status Rapid Review Complete
HTA ID 23008
Drug House dust mite allergen extract
Brand Actair®
Indication Dermatophagoides pteronyssinus and Dermatophagoides farinae in equal parts (Actair®) is indicated for the treatment of moderate-to-severe house dust mite (HDM)–induced allergic rhinitis (AR) or rhinoconjunctivitis diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test [SPT] and/or specific immunoglobulin E [IgE]) in adolescents (aged 12-17 years) and adults.
Assessment Process
Rapid review commissioned 10/02/2023
Rapid review completed 24/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM allergen extracts compared with the current standard of care.